Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

BACKGROUND: COU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary Authorizat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Houédé, Nadine, Beuzeboc, Philippe, Gourgou, Sophie, Tosi, Diego, Moise, Laura, Gravis, Gwenaëlle, Delva, Remy, Fléchon, Aude, Latorzeff, Igor, Ferrero, Jean-Marc, Oudard, Stéphane, Tartas, Sophie, Laguerre, Brigitte, Topart, Delphine, Roubaud, Guilhem, Agherbi, Hanane, Rebillard, Xavier, Azria, David
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4392747/
https://ncbi.nlm.nih.gov/pubmed/25884302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1257-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak